黄檀素对心肌缺血/再灌注损伤的治疗作用及机制研究

Study on the Therapeutic Effect and Mechanism of Dalbergin on Myocardial Ischemia/Reperfusion Injury

目的:探讨黄檀素(DAL)对小鼠心肌缺血/再灌注(MI/R)损伤心肌的治疗作用及其作用机制。方法:选择成年雄性C57 BL/6J小鼠随机分为假手术组(Sham)、模型组(MI/R)、地尔硫组(Diltiazem)和DAL低、中、高剂量组(10、30、90 mg/kg/d),每组10只。结扎小鼠冠状动脉左前降支(LAD),缺血30 min,再灌注1 h建立小鼠MI/R损伤模型。术后第1天起,Sham组、MI/R组小鼠均灌胃等体积生理盐水,Diltiazem组、DAL各剂量组小鼠灌胃相应药液,每日1次,连续7 d。给药结束后检测小鼠血清中肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)活性及肿瘤坏死因-α(TNF-α)、白细胞介素-6(IL-6)含量;检测小鼠心肌组织中超氧化歧化酶(SOD)活性和丙二醛(MDA)含量;苏木精-伊红染色(HE)检测心肌损伤病理形态;Western Blot检测心肌组织中Akt和P-Akt的蛋白水平表达变化;超声检测左室舒张末内径(ESD)、左室舒张末容积(EDV)、射血分数(EF)和短轴缩短率(FS)。结果:DAL可以减轻小鼠血清中CK-MB、LDH活性及TNF-α、IL-6含量;升高小鼠心肌组织中SOD活性,减少MDA生成;增加p-Akt的蛋白水平表达,减轻心肌组织病理损伤,改善心脏功能。结论:DAL可以通过增加Akt磷酸化促进心肌细胞存活,减轻心肌组织病理损伤,进而抑制小鼠MI/R损伤,改善心脏功能,最终发挥心肌治疗作用。

Objective: To explore the therapeutic effect of Dalbergin(DAL) on myocardial ischemia/reperfusion(MI/R) injury in mice and its mechanism. Methods: Adult male C57 BL/6J mice were randomly divided into sham operation group, model group, diltiazem group, DAL low, medium, and high dose groups(10, 30, 90 mg/kg/d), with 10 mice in each group. The mouse left anterior descending coronary artery(LAD) was ligated, ischemia for 30 minutes, and reperfusion for 1 hour to establish a mouse MI/R injury model.From the first day after the operation, mice in the sham operation group and model group were intragastrically administered with equal volume of normal saline, and mice in each dose group of DAL were intragastrically administered with the corresponding liquid once a day for 7 consecutive days. After the administration, the creatine kinase isoenzyme(CK-MB), lactate dehydrogenase(LDH), tumor necrosis factor-α(TNF-α) and interleukin-6(IL-6) in the serum of mice were detected;The superoxide dismutase(SOD) activity and malondialdehyde(MDA) content in mouse myocardial tissue were detection;The myocardial injury pathology were detected by hematoxylin-eosin(HE) staining;Western Blot detection of Akt and P-Akt in myocardial tissue protein level expression changes;Ultrasound detection of left ventricular end diastolic diameter(ESD), left ventricular end diastolic volume(EDV), ejection fraction(EF) and short axis shortening rate(FS). Results: DAL can reduce the activity of CK-MB and LDH and the content of TNF-α and IL-6 in the serum of mice, increase the activity of SOD in mouse myocardial tissue and reduce the production of MDA(P<0.01 or P<0.05), increase the expression of p-Akt protein, reduce pathological damage of myocardial tissue, and improve cardiac function. Conclusions: DAL can promote myocardial cell survival by increasing Akt phosphorylation, reduce myocardial tissue pathological damage, inhibit MI/R damage in mice, improve cardiac function and ultimately play a role in myocardial therapy.